There's no shortage of investing strategies, but growth investing remains one of the most popular approaches. Stocks that climb 50%, 100%, or more over a relatively short period rarely do so by chance. In many cases, the move is driven by improving fundamentals, a successful new product, expanding demand, or another development that changes how the market views the business.

55% Off TipRanks

• Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
• Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Of course, a rising share price alone is never enough to justify an investment. Past performance does not guarantee future returns. Still, high-flying stocks often have business trends working in their favor, making them worthy of a closer look. And no, we're not talking about another GameStop-style short squeeze.

With that in mind, we turned to the TipRanks database to find two stocks that have posted triple-digit gains so far this year. But are they capable of climbing even higher? To answer that question, we also looked at Wall Street's latest views, where analysts continue to rate both names favorably, suggesting there could still be room for further gains. Here's why they remain optimistic.

Tango Therapeutics (TNGX)

Let's start with a biotech company, Tango Therapeutics. This firm is working on new treatments in oncology, and is focusing its work on finding novel drug targets that will make up the next generation of cancer treatments. Tango's work leverages genetic principles to create precision medicines based on synthetic lethality; following this approach, Tango is building therapies that aim to target critical oncological targets. Tango has described its work with precision oncology as allowing targeting in new areas, which it defines as 'tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.'

Tango has put together an impressive pipeline, with new drug candidates targeting pancreatic and lung cancers, as well as glioblastomas. These are all dangerous cancers, known for resisting treatment – Tango's approach uses a state-of-the-art CRISPR-based target discovery engine to locate novel targets in genetically defined cancers – and to expand the roster of currently-limited treatment options.

The main excitement for investors comes from the recent data release regarding vopimetostat, a new drug for the treatment of MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). The drug is being tested against this condition in combination with daraxonrasib. Initial data from an ongoing Phase 1/2 trial were released on June 8 and showed durability of treatment, 'with 90% of PDAC patients still progression free at 6 months of follow-up.'

Pancreatic cancer has a history of being both highly lethal and highly resistant to treatment – so finding a drug candidate that offers high potential for treatment is big news. The success of this leading oncology drug over the past year has supported Tango's stock, which is up 245% this year.

Additionally, the company moved to raise capital through a sale of stock, putting 18,166,667 shares on the market at $30 each. The company raised a net of $566.6 million, stating that this is enough to fund upcoming Phase 3 trials.

Among the bulls is Jefferies analyst Maury Raycroft, who believes the recent data still leave room for meaningful upside.

"Additional upside can be justified, given that initial vopimetostat + daraxonrasib data point to a potentially large benefit vs daraxonrasib monotherapy, where TNGX could unlock a $4B+ opportunity by addressing 25%-40% of PDAC patients with MTAP deletion. 2026 catalysts include a larger update with expected 24-25 evaluable patients, with ORR and more mature durability at a med conference later this year (+40%-50%/-50%; est ESMO or Triple), along with potential alignment on a first-line PDAC pivotal trial and/or a second-line accelerated approval path(s)," Raycroft noted.

Based on this bullish stance, Raycroft puts a Buy rating on the stock, with a $60 price target that implies a one-year upside of ~96%. (To watch Raycroft's track record, click here)

Overall, the bulls are clearly in charge. TNGX has a Strong Buy consensus based on 11 recent analyst ratings, with 10 Buys and just one Hold. At $30.64, Wall Street's average $42 price target points to 37% upside over the next year. (See TNGX stock forecast)